FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/19/2025
Back to search
Official data from USPTO
MYOSCREEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MYOSCREEN
ST13
US500000079382428Class
5, 9, 42
Filing
79382428
Registration
7691258
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/03/2026
Trademark type
Word
Nice classes
5, 9, 42
Filing date
05/26/2023
Registration date
02/18/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/18/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
FR
Examiner
REID, CAILE MAUREEN
Law office
N50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CYTOO
Representatives
Steven J. Solomon Tucker Ellis LLP
Technical classification
Nice Classes
Class 5Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productsnamely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; veterinary productsnamely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; sanitary preparations for medical use; chemical and biological preparations for medical usenamely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseasesbiological preparations for pharmaceutical use being biological preparations for use in cell cultures for medical purposes
Class 9
Quality control and testing devices namely culture plates to test and conduct quality control in the field of biologybiotechnology and pharmacy; downloadable software for the collectionprocessing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instrumentsnamely computer hardware and downloadable software for data analysisdatabase managementdata processingin the field of life science research and the pharmaceutical industry market and diagnostics
Class 42
Medicalbiotechnologicalpharmaceutical research; research and development of chemicalbiological and scientific products and materials in the biologicalbiotechnologicalmedicaldiagnostic and pharmaceutical fields; scientific researchadvisory and information services in the medicalbiotechnologicalpharmaceuticaldiagnostictechnological and industrial fields; design and development of computerssoftware and computer platforms; technical testing namely technological testing in the scientificbiologicalbiotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testingtechnical testing namelytechnological testing in the scientificbiologicalbiotechnological and medical fieldsscientific research advisory services with respect to scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imagingin the scientificbiologicalbiochemicalmolecular-biologybiotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientificbiologicalbiochemicalmolecular-biologybiotechnological and medical fields; diagnostic and industrial research in the biologicalbiotechnological and medical fields
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/31/2025
FIMP
FINAL DISPOSITION PROCESSED
08/31/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/18/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/19/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/31/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/31/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/31/2024
PUBO
PUBLISHED FOR OPPOSITION
12/31/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/25/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/22/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
10/22/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/22/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
10/22/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/22/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/23/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/23/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/23/2024
RFNT
REFUSAL PROCESSED BY IB
04/16/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/25/2024
RFRR
REFUSAL PROCESSED BY MPU
03/25/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/02/2024
CNRT
NON-FINAL ACTION WRITTEN
03/01/2024
DOCK
ASSIGNED TO EXAMINER
02/20/2024
MAFR
APPLICATION FILING RECEIPT MAILED
11/07/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/03/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/02/2023
Continuous trademark protection
Get notified about every new filing that threatens MYOSCREEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.